Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Medpace Holdings IncTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.02B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Medpace Holdings Inc is far larger — about 9.5× Vir Biotechnology Inc. Common Stock's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vir Biotechnology Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

MEDPVIR
Market Cap
$17.02B$1.80B
Volume
155,2501,782,836
Sector
HealthHealth
52-Week High
$630.19$11.78
52-Week Low
$393.42$5.12
Typical Hold Time
14 Days0 Days
Enterprise Value
$16.63B$1.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.

MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MEDP

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →